(MENAFN- GlobeNewsWire - Nasdaq) The burgeoning field of Software as a Medical Device (SaMD) offers opportunities for innovation in healthcare monitoring and delivery through mobile apps. Regulatory focus by the FDA on "device software functions" underscores the need for compliance in cybersecurity, validation, and documentation, impacting the medical device industry's landscape for product development and market entry.

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Mobile Medical Device Apps and the FDA - Classification, Regulatory Requirements and Cybersecurity" training has been added to ResearchAndMarkets's offering.
The rapid expansion and broad applicability of software functions / applications deployed on mobile or other general-purpose computing platforms has created concerns with industry and the US FDA. This has resulted in the FDA focusing on the subset of software functions dealing with medical issues which the Agency intends to apply its authority. What are these issues / software app claims, and how will this affect the medical device industry?
FDA refers to software functions that are device functions as "device software functions." These may include "Software as a Medical Device (SaMD)" and "Software in a Medical Device (SiMD)." If a software function that meets the definition of a device is deployed on a mobile platform, it may be referred to as a "mobile medical app."
These new technologies use terms such as "mobile medical apps," "mobile medical app manufacturers," "device software functions," and "device software function manufacturers," and are not always specific to whether the function is deployed on a mobile platform or other general-purpose computing platform.
What are the FDA definitions and regulatory expectations? What is also required for effective and real-world software verification and validation in such use environments? This discussion will focus on what is and what is not recognized as a Mobile App for regulation as a medical device by the US FDA. Cybersecurity, CGMP, 21 CFR Part 11 and submission considerations will be discussed as well.
Some of these new mobile apps / software functions are specifically targeted to assisting individuals in their own health and wellness management. Others are targeted to healthcare providers as tools to improve and facilitate the delivery of patient care. These software devices include products that feature one or more software components, parts, or accessories, as well as devices that are composed solely of software.
Certain software functions / mobile apps that are device functions can pose potential risks to public health, and these are the subject of FDA concern and focused regulation.
Mobile medical apps, as defined here, include only those mobile apps that:

• Meet the definition of a device; and either
• Are intended to be used as an accessory to a regulated medical device; or
• Are intended to transform a mobile platform into a regulated medical device.
• What are they as defined by the FDA, what are not? Requirements? Cybersecurity concerns, validation and documentation requirements will also be addressed.

Who Should Attend:

• Senior Management in Device and Combination Products
• Quality Assurance Departments
• Quality Control Departments
• Research and Development Departments
• Software Development and Programming Departments
• Documentation Departments
• Manufacturing Departments
• Engineering Departments
• Production Departments
• Operations Departments
• Validation Departments
• Device Testing Teams
• Marketing Departments
• Consultants
• Everyone tasked with product, process, electronic records software V&V responsibilities

Key Topics Covered:

• Mobile Health Apps/Functions - What are they?
• SaMD and SiMD
• FDA's Functionality vs. Platform enforcement approach
• Intended Use - not just a term
• Software functions that are, or are NOT, a "device"
• FDA's regulatory approach; Examples
• Design, manufacturing and additional requirements
• Cybersecurity requirements
• Validation and unique documentation requirements

Speaker
John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 36 years experience in U.S. FDA-regulated industries, 22 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files, CAPA systems and analysis.
He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. He writes a recurring column for the Journal of Validation Technology. John is a graduate of UCLA.
For more information about this training visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN05112025004107003653ID1110300172